Background
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides and a decreased lifetime risk of atherosclerotic cardiovascular disease....Conclusions
Editing of ANGPTL3 was associated with few adverse events and resulted in reductions from baseline in ANGPTL3 levels. (Funded by CRISPR Therapeutics; Australia New Zealand Clinical Trials Registry number, ACTRN12623000809639.)
pull down to refresh
related posts
107 sats \ 1 reply \ @k00b 8 Nov
Whoa I didn't know we were doing gene editing trials in humans for things like high cholesterol. I assumed we'd spend another decade or two exploring gene therapy in patients with terminal genetic diseases primarily. Medicine is about to turn up.
reply
60 sats \ 0 replies \ @itsrealfake 8 Nov
ya boiiii. next 15 years are gonna be nutso for healthspan extension
reply
0 sats \ 0 replies \ @ProofOfWorkFitness 8 Nov
Heart disease or other cardiovascular diseases are the biggest killers of Americans so if we take that off the table then you're going to need even more Bitcoin to keep going and retirement. Stack SATs Get Fit
reply